Baltimore, MD – August 4, 2015 – WellDoc®, a leading expert in mobile health innovation, is participating in the American Association of Diabetes Educators’ annual meeting in New Orleans, August 5-8. A series of educational sessions will feature the commercial experience and implementation of BlueStar®, the first mobile prescription therapy for adults with type 2 diabetes.
A panel comprised of diabetes educators who have been using BlueStar in their practices will share case studies and lessons learned regarding their experiences implementing BlueStar®. The session, “Mobile Prescription Therapy: Opportunities for Educators to Improve Patient Engagement & Outcomes,” features Kathy Gold, MS, RN, CDE, Director of Outreach and Education Diabetes Research and Wellness Foundation, Washington, DC; John Motsko, RPh, Apple Discount Drugs, Apple Drugs Diabetes Center, Salisbury, MD; and Debra Nelson, MA, RN, CDE, Diabetes Nurse Educator, University of Maryland Diabetes Center, Baltimore, MD. The panel will take place on Thursday, August 6 at 9:15 a.m. Central time and offers continuing education credits.
Charlene Quinn, Ph.D., RN, University of Maryland School of Medicine, will present “The Use of mHealth to Manage and Improve Diabetes.” Dr. Quinn is the primary author of WellDoc’s registered clinical trial, “Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for Blood Glucose Control,” published in Diabetes Care, September 20111 . Dr. Quinn will discuss current evidence in mobile health on Wednesday, August 5 at 2:00 p.m. Central time for continuing education credits.
WellDoc will also present two posters on Friday, August 7, 2015 highlighting the importance of the diabetes educator in implementing mobile health and enriching Diabetes Self-Management Education and Support (DSME/S) programs. These posters can be found on the corporate website:
- Educators: Go Mobile & Join the Digital Revolution!
- Transform Your DSME/S Program: Leverage the Value of Mobile Health
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized the first mobile prescription therapy, BlueStar®, for adults with type 2 diabetes. Mobile prescription therapy fills the support gap between patients and providers during the 8700 hours that individuals are living their lives outside the healthcare system. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence since 2008 and as recently as June 2015 has presented real-world patient engagement and clinical outcomes at the American Diabetes Association’s (ADA) 75th Scientific Session. BlueStar is recognized by the ADA on its website as the first and only in a new class of diabetes treatment known as mobile prescription therapy (MPT). For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.
1 Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL. Cluster-randomized trial of
a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care. 2011
Sep;34(9):1934-42. Erratum in: Diabetes Care. 2013 Nov;36(11):3850.